Document Detail

The Frequency of Adjusted Renal Dosing of Tenofovir DF and Its Effects on Patient Outcomes.
MedLine Citation:
PMID:  23204147     Owner:  NLM     Status:  Publisher    
Tenofovir disoproxil fumarate (TDF), a nucleotide reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV) and hepatitis B, is renally eliminated and has been associated with renal toxicities. Dose adjustments are recommended for patients with creatinine clearance (CrCL) <50 mL/min. We retrospectively determined the frequency in which HIV clinic providers adjusted TDF doses in patients with CrCL <50 mL/min over a 2-year period and compared clinical outcomes in patients who had TDF dose adjustments based on CrCL <50 mL/min versus those who did not. Thirty-nine patients with CrCL <50 mL/min were identified. Dose-adjusted patients (N = 9) continued their TDF-based antiretroviral regimens for 21 months longer following the first CrCL < 50 mL/min (P = .0193) and had gains in CD4 cell counts over 12 months (P = .0009). There were no statistically significant differences in CrCL or percentage of patients with detectable HIV-1 RNA at 6 and 12 months following first CrCL <50 mL/min in those who did versus did not have a TDF dose adjustment. In summary, HIV providers often failed to dose-adjust TDF in patients with CrCL <50 mL/min, but dose-adjusted patients appeared to stay on their TDF-based regimens longer and have greater gains in CD4 cells. Larger, prospective studies are needed to validate these results.
Jacob A Langness; Jason T Hindman; Steven C Johnson; Jennifer J Kiser
Related Documents :
9602867 - Effect of isotretinoin therapy on natural killer cell activity in patients with xeroder...
9184197 - A model for quantitative measurement of sulfur mustard skin lesions in the rabbit ear.
572917 - Pyrimidine dimer excision in human cells and skin cancer.
12584677 - Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically...
2052677 - Radiographic fallopian tube recanalization: absorbed ovarian radiation dose.
7083217 - Safety assessment of new anticancer compound, mitoxantrone, in beagle dogs: comparison ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-2
Journal Detail:
Title:  Journal of pharmacy practice     Volume:  -     ISSN:  1531-1937     ISO Abbreviation:  J Pharm Pract     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8900945     Medline TA:  J Pharm Pract     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
University of Colorado Hospital, Department of Pharmacy, Aurora, CO, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical Pearls for Initiating and Utilizing Liraglutide in Patients With Type 2 Diabetes.
Next Document:  Pharmacotherapy of Lung Transplantation: An Overview.